Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.53 which represents a decrease of $-0.02 or -3.64% from the prior close of $0.55. The stock opened at $0.54 and touched a low ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report) ...

In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN), currently trading near its 52-week low of $0.56, recently disclosed ...

Mersana Therapeutics Inc (MRSN) stock saw a modest uptick, ending the day at $0.63 which represents a slight increase of $0.01 or 1.61% from the prior close of $0.62. The stock opened at $0.62 and ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) today. The company’s ...

Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $4.00 ...